Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 463

1.

A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).

Kapoor R, Deek MP, McIntyre R, Raman N, Kummerlowe M, Chen I, Gaver M, Wang H, Denmeade S, Lotan T, Paller C, Markowski M, Carducci M, Eisenberger M, Beer TM, Song DY, DeWeese TL, Hearn JW, Greco S, DeVille C, Desai NB, Heath EI, Liauw S, Spratt DE, Hung AY, Antonarakis ES, Tran PT.

BMC Cancer. 2019 Jun 13;19(1):572. doi: 10.1186/s12885-019-5805-z.

PMID:
31196032
2.

Key considerations when reviewing subsequent primary cancers following radiotherapy.

Kishan AU, Wang C, Steinberg ML, Spratt DE.

Lancet Oncol. 2019 Jun;20(6):e291. doi: 10.1016/S1470-2045(19)30227-X. No abstract available.

PMID:
31162098
3.

The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement.

Cooperberg MR, Carroll PR, Dall'Era MA, Davies BJ, Davis JW, Eggener SE, Feng FY, Lin DW, Morgan TM, Morgans AK, Spratt DE, Taneja SS, Penson DF.

Eur Urol. 2019 May 23. pii: S0302-2838(19)30417-8. doi: 10.1016/j.eururo.2019.05.013. [Epub ahead of print]

PMID:
31128968
4.

Xenograft-based platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma.

Zhao SG, Yu M, Spratt DE, Chang SL, Feng FY, Kim MM, Speers CW, Carlson BL, Mladek AC, Lawrence TS, Sarkaria JN, Wahl DR.

Neuro Oncol. 2019 May 23. pii: noz090. doi: 10.1093/neuonc/noz090. [Epub ahead of print]

PMID:
31121035
5.

Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.

Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, Amling CL, Aronson WJ, Kane CJ, Terris MK, Zumsteg ZS, Butler S, Osborne JR, Morgan TM, Mehra R, Salami SS, Kishan AU, Wang C, Schaeffer EM, Roach M 3rd, Pisansky TM, Shipley WU, Freedland SJ, Sandler HM, Halabi S, Feng FY, Dignam JJ, Nguyen PL, Schipper MJ, Spratt DE.

JAMA Oncol. 2019 May 23. doi: 10.1001/jamaoncol.2019.0826. [Epub ahead of print]

PMID:
31120534
6.

Active Surveillance for Low-Risk Prostate Cancer in Black Patients.

Butler S, Muralidhar V, Chavez J, Fullerton Z, Mahal A, Nezolosky M, Vastola M, Zhao SG, D'Amico AV, Dess RT, Feng FY, King MT, Mouw KW, Spratt DE, Trinh QD, Nguyen PL, Rebbeck TR, Mahal BA.

N Engl J Med. 2019 May 23;380(21):2070-2072. doi: 10.1056/NEJMc1900333. No abstract available.

PMID:
31116925
7.

Thyroid Cancer Brain Metastasis: Survival and Genomic Characteristics of a Large Tertiary Care Cohort.

Osborne JR, Kondraciuk JD, Rice SL, Zhou X, Knezevic A, Spratt DE, Sabra M, Larson SM, Grewal RK.

Clin Nucl Med. 2019 Jul;44(7):544-549. doi: 10.1097/RLU.0000000000002618.

PMID:
31107749
9.

Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure.

Jackson WC, Suresh K, Tumati V, Dess RT, Soni PD, Zhao SG, Zumsteg ZS, Hannan R, Hollenbeck BK, George A, Kaffenberger SD, Salami SS, Hearn JWD, Morgan TM, Mehra R, Schipper M, Feng FY, Desai NB, Spratt DE.

Eur Urol Oncol. 2018 Sep;1(4):276-282. doi: 10.1016/j.euo.2018.04.014. Epub 2018 Sep 28.

PMID:
31100248
10.

Tumor.

Elder JB, Sherman JH, Prevedello DM, Szerlip NJ, Spratt DE, Shaikhouni A, Mohyeldin A, Perez-Roman RJ, Buttrick SS, Ali SC, Komotar RJ, Todeschini A, Shahein M, Revuelta JM, Hardesty D, Carrau RL, Zada G, Giannotta S, Dornbos D, Lonser RR.

Oper Neurosurg (Hagerstown). 2019 May 17. pii: opz100. doi: 10.1093/ons/opz100. [Epub ahead of print] No abstract available.

PMID:
31099848
11.

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA.

J Natl Compr Canc Netw. 2019 May 1;17(5):479-505. doi: 10.6004/jnccn.2019.0023.

PMID:
31085757
12.

The current state of randomized clinical trial evidence for prostate brachytherapy.

Dess RT, Soni PD, Jackson WC, Berlin A, Cox BW, Jolly S, Efstathiou JA, Feng FY, Kishan AU, Stish BJ, Pisansky TM, Spratt DE.

Urol Oncol. 2019 May 3. pii: S1078-1439(19)30142-5. doi: 10.1016/j.urolonc.2019.04.009. [Epub ahead of print] Review.

PMID:
31060795
13.

What Are We Even Looking At?

Spratt DE.

Int J Radiat Oncol Biol Phys. 2019 Jun 1;104(2):264-265. doi: 10.1016/j.ijrobp.2019.03.030. No abstract available.

PMID:
31047625
14.

In Reply to Wilkins et al.

Spratt DE.

Int J Radiat Oncol Biol Phys. 2018 Dec 1;102(5):1597-1598. doi: 10.1016/j.ijrobp.2018.08.008. No abstract available.

PMID:
31014791
15.

Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.

Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C Jr, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU.

Eur Urol. 2019 Apr 13. pii: S0302-2838(19)30208-8. doi: 10.1016/j.eururo.2019.03.022. [Epub ahead of print]

PMID:
30992160
16.

Computed Tomography Myelosimulation Versus Magnetic Resonance Imaging Registration to Delineate the Spinal Cord During Spine Stereotactic Radiosurgery.

Beeler WH, Paradis KC, Gemmete JJ, Chaudhary N, Kim MM, Smith SR, Paradis E, Matuszak MM, Park P, Archer PG, Szerlip NJ, Spratt DE.

World Neurosurg. 2019 Feb;122:e655-e666. doi: 10.1016/j.wneu.2018.10.118. Epub 2018 Oct 26.

PMID:
30992117
17.

Dose-intensified chemoradiation is associated with altered patterns of failure and favorable survival in patients with newly diagnosed glioblastoma.

Kim MM, Speers C, Li P, Schipper M, Junck L, Leung D, Orringer D, Heth J, Umemura Y, Spratt DE, Wahl DR, Cao Y, Lawrence TS, Tsien CI.

J Neurooncol. 2019 Jun;143(2):313-319. doi: 10.1007/s11060-019-03166-3. Epub 2019 Apr 11.

PMID:
30977058
18.

STAMPEDE: Is Radiation Therapy to the Primary a New Standard of Care in Men with Metastatic Prostate Cancer?

Choudhury A, Chen RC, Henry A, Mistry H, Mitin T, Pinkawa M, Spratt DE.

Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):33-35. doi: 10.1016/j.ijrobp.2018.12.040. No abstract available.

PMID:
30967237
19.

Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies.

Jackson WC, Silva J, Hartman HE, Dess RT, Kishan AU, Beeler WH, Gharzai LA, Jaworski EM, Mehra R, Hearn JWD, Morgan TM, Salami SS, Cooperberg MR, Mahal BA, Soni PD, Kaffenberger S, Nguyen PL, Desai N, Feng FY, Zumsteg ZS, Spratt DE.

Int J Radiat Oncol Biol Phys. 2019 Apr 6. pii: S0360-3016(19)30612-1. doi: 10.1016/j.ijrobp.2019.03.051. [Epub ahead of print]

PMID:
30959121
20.

Comparison of Population-Based Observational Studies With Randomized Trials in Oncology.

Soni PD, Hartman HE, Dess RT, Abugharib A, Allen SG, Feng FY, Zietman AL, Jagsi R, Schipper MJ, Spratt DE.

J Clin Oncol. 2019 May 10;37(14):1209-1216. doi: 10.1200/JCO.18.01074. Epub 2019 Mar 21.

PMID:
30897037
21.

Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer.

Liu D, Takhar M, Alshalalfa M, Erho N, Shoag J, Jenkins RB, Karnes RJ, Ross AE, Schaeffer EM, Rubin MA, Trock B, Klein EA, Den RB, Tomlins SA, Spratt DE, Davicioni E, Sboner A, Barbieri CE.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00036. Epub 2018 Jul 24.

22.

Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015.

Mahal BA, Butler S, Franco I, Spratt DE, Rebbeck TR, D'Amico AV, Nguyen PL.

JAMA. 2019 Feb 11. doi: 10.1001/jama.2018.19941. [Epub ahead of print] No abstract available.

PMID:
30743264
23.

Rapid and efficient purification of Drosophila homeodomain transcription factors for biophysical characterization.

Orlomoski R, Bogle A, Loss J, Simons R, Dresch JM, Drewell RA, Spratt DE.

Protein Expr Purif. 2019 Jun;158:9-14. doi: 10.1016/j.pep.2019.02.001. Epub 2019 Feb 7.

PMID:
30738927
24.

Combination therapies in prostate cancer: proceed with caution.

Spratt DE.

Lancet Oncol. 2019 Mar;20(3):321-323. doi: 10.1016/S1470-2045(18)30929-X. Epub 2019 Feb 6. No abstract available.

PMID:
30738781
25.

Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer.

Kishan AU, Dang A, Katz AJ, Mantz CA, Collins SP, Aghdam N, Chu FI, Kaplan ID, Appelbaum L, Fuller DB, Meier RM, Loblaw DA, Cheung P, Pham HT, Shaverdian N, Jiang N, Yuan Y, Bagshaw H, Prionas N, Buyyounouski MK, Spratt DE, Linson PW, Hong RL, Nickols NG, Steinberg ML, Kupelian PA, King CR.

JAMA Netw Open. 2019 Feb 1;2(2):e188006. doi: 10.1001/jamanetworkopen.2018.8006.

26.

Bringing Prostate Cancer Germline Genetics into Clinical Practice.

Das S, Salami SS, Spratt DE, Kaffenberger SD, Jacobs MF, Morgan TM.

J Urol. 2019 Feb 5:101097JU0000000000000137. doi: 10.1097/JU.0000000000000137. [Epub ahead of print]

PMID:
30730411
27.

Application of a Prognostic Stratification System for High-risk Prostate Cancer to Patients Treated With Radiotherapy: Implications for Treatment Optimization.

Foster B, Jackson W, Foster C, Dess R, Abu-Isa E, McLaughlin PW, Merrick G, Hearn J, Spratt D, Liauw S, Hamstra D.

Am J Clin Oncol. 2019 Apr;42(4):382-390. doi: 10.1097/COC.0000000000000521.

PMID:
30724780
28.

A subset of calcium-binding S100 proteins show preferential heterodimerization.

Spratt DE, Barber KR, Marlatt NM, Ngo V, Macklin JA, Xiao Y, Konermann L, Duennwald ML, Shaw GS.

FEBS J. 2019 May;286(10):1859-1876. doi: 10.1111/febs.14775. Epub 2019 Feb 21.

PMID:
30719832
29.

Metastatic castration resistant prostate cancer with squamous cell, small cell, and sarcomatoid elements-a clinicopathologic and genomic sequencing-based discussion.

Weindorf SC, Taylor AS, Kumar-Sinha C, Robinson D, Wu YM, Cao X, Spratt DE, Kim MM, Lagstein A, Chinnaiyan AM, Mehra R.

Med Oncol. 2019 Feb 2;36(3):27. doi: 10.1007/s12032-019-1250-8.

PMID:
30712214
30.

Individual and Population Comparisons of Surgery and Radiotherapy Outcomes in Prostate Cancer Using Bayesian Multistate Models.

Beesley LJ, Morgan TM, Spratt DE, Singhal U, Feng FY, Furgal AC, Jackson WC, Daignault S, Taylor JMG.

JAMA Netw Open. 2019 Feb 1;2(2):e187765. doi: 10.1001/jamanetworkopen.2018.7765.

31.

Prostate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Scores.

Mahal BA, Alshalalfa M, Spratt DE, Davicioni E, Zhao SG, Feng FY, Rebbeck TR, Nguyen PL, Huang FW.

Eur Urol. 2019 Jun;75(6):1038-1040. doi: 10.1016/j.eururo.2019.01.010. Epub 2019 Jan 22. No abstract available.

PMID:
30683576
32.

Utilization of Salvage Radiation Therapy for Biochemical Recurrence After Radical Prostatectomy.

Hawken SR, Spratt DE, Qi J, Linsell SM, Cher ML, Ghani KR, Miller DC, Montie JE, Morgan TM; Michigan Urological Surgery Improvement Collaborative.

Int J Radiat Oncol Biol Phys. 2019 Jan 23. pii: S0360-3016(19)30046-X. doi: 10.1016/j.ijrobp.2019.01.006. [Epub ahead of print]

PMID:
30682490
34.

National practice patterns for lymph node irradiation in 197,000 men receiving external beam radiotherapy for localized prostate cancer.

Weiner AB, Ko OS, Zhu A, Spratt DE, Hu JC, Schaeffer EM.

Urol Oncol. 2019 Jun;37(6):353.e1-353.e8. doi: 10.1016/j.urolonc.2018.12.022. Epub 2019 Jan 2.

PMID:
30611643
35.

Adverse events in radiation oncology: A case series from wake up safe, the pediatric anesthesia quality improvement initiative.

Christensen RE, Nause-Osthoff RC, Waldman JC, Spratt DE, Hearn JWD.

Paediatr Anaesth. 2019 Mar;29(3):265-270. doi: 10.1111/pan.13567. Epub 2019 Jan 29.

PMID:
30580487
36.

Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas.

Zhao SG, Chen WS, Das R, Chang SL, Tomlins SA, Chou J, Quigley DA, Dang HX, Barnard TJ, Mahal BA, Gibb EA, Liu Y, Davicioni E, Duska LR, Posadas EM, Jolly S, Spratt DE, Nguyen PL, Maher CA, Small EJ, Feng FY.

Clin Cancer Res. 2019 Apr 15;25(8):2450-2457. doi: 10.1158/1078-0432.CCR-18-3121. Epub 2018 Dec 20.

PMID:
30573691
37.

The utility of upper urinary tract urine cytology before and after application of the Paris system.

Simon CT, Skala SL, Magers MJ, Weizer A, Kaffenberger SD, Chinnaiyan AM, Spratt DE, Montgomery J, Mehra R, Lew M.

Diagn Cytopathol. 2019 May;47(5):421-427. doi: 10.1002/dc.24127. Epub 2018 Dec 19.

PMID:
30569543
38.

Precision Medicine for Localized Prostate Cancer: Time to Move Beyond NCCN Risk Stratification?

Zumsteg ZS, Spratt DE.

Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):92-94. doi: 10.1016/j.ijrobp.2018.09.040. Epub 2018 Dec 12. No abstract available.

PMID:
30563670
39.

Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.

Yang DD, Mahal BA, Muralidhar V, Martin NE, Orio PF, Mouw KW, King MT, Choueiri TK, Trinh QD, Hoffman KE, Spratt DE, Feng FY, Nguyen PL.

Eur Urol. 2019 Jan;75(1):35-41. doi: 10.1016/j.eururo.2018.08.033. Epub 2018 Oct 24.

PMID:
30554605
40.

Reassessment of Routine Midstream Culture in Diagnosis of Urinary Tract Infection.

Sathiananthamoorthy S, Malone-Lee J, Gill K, Tymon A, Nguyen TK, Gurung S, Collins L, Kupelian AS, Swamy S, Khasriya R, Spratt DA, Rohn JL.

J Clin Microbiol. 2019 Feb 27;57(3). pii: e01452-18. doi: 10.1128/JCM.01452-18. Print 2019 Mar.

41.

Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma.

Simon CT, Skala SL, Weizer AZ, Ambani SN, Chinnaiyan AM, Palapattu G, Hafez K, Magers MJ, Kaffenberger SD, Spratt DE, Montgomery JS, Morgan TM, Udager AM, Lew M, Mehra R.

Hum Pathol. 2019 Apr;86:76-84. doi: 10.1016/j.humpath.2018.11.021. Epub 2018 Dec 8.

PMID:
30537495
43.

Airway microbiome in adult survivors of extremely preterm birth: the EPICure study.

Rofael SAD, McHugh TD, Troughton R, Beckmann J, Spratt D, Marlow N, Hurst JR.

Eur Respir J. 2019 Jan 10;53(1). pii: 1801225. doi: 10.1183/13993003.01225-2018. Print 2019 Jan.

PMID:
30464016
44.

Resveratrol Sustains Insulin-Degrading Enzyme Activity toward Aβ42.

Krasinski CA, Ivancic VA, Zheng Q, Spratt DE, Lazo ND.

ACS Omega. 2018 Oct 31;3(10):13275-13282. doi: 10.1021/acsomega.8b01913. Epub 2018 Oct 16.

45.

Transcriptomic heterogeneity in multifocal prostate cancer.

Salami SS, Hovelson DH, Kaplan JB, Mathieu R, Udager AM, Curci NE, Lee M, Plouffe KR, de la Vega LL, Susani M, Rioux-Leclercq N, Spratt DE, Morgan TM, Davenport MS, Chinnaiyan AM, Cyrta J, Rubin MA, Shariat SF, Tomlins SA, Palapattu GS.

JCI Insight. 2018 Nov 2;3(21). pii: 123468. doi: 10.1172/jci.insight.123468.

46.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Oct 18;175(3):889. doi: 10.1016/j.cell.2018.10.019. No abstract available.

47.

Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis.

Kishan AU, Wang X, Seiferheld W, Collette L, Sandler KA, Sandler HM, Bolla M, Maingon P, De Reijke T, Hanks GE, Nickols NG, Rettig M, Drakaki A, Reiter RE, Spratt DE, Kupelian PA, Steinberg ML, King CR.

JAMA Oncol. 2019 Jan 1;5(1):91-96. doi: 10.1001/jamaoncol.2018.3732.

PMID:
30326032
48.

The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.

Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, Spratt DE, Feng FY.

J Natl Cancer Inst. 2019 Mar 1;111(3):301-310. doi: 10.1093/jnci/djy141.

PMID:
30321406
49.

Differences in the subgingival microbial population of chronic periodontitis in subjects with and without type 2 diabetes mellitus-a systematic review.

Liu LS, Gkranias N, Farias B, Spratt D, Donos N.

Clin Oral Investig. 2018 Nov;22(8):2743-2762. doi: 10.1007/s00784-018-2660-2. Epub 2018 Oct 10.

PMID:
30306333
50.

Enzyme kinetics from circular dichroism of insulin reveals mechanistic insights into the regulation of insulin-degrading enzyme.

Ivancic VA, Krasinski CA, Zheng Q, Meservier RJ, Spratt DE, Lazo ND.

Biosci Rep. 2018 Nov 7;38(6). pii: BSR20181416. doi: 10.1042/BSR20181416. Print 2018 Dec 21.

Supplemental Content

Loading ...
Support Center